Insider Selling: Phreesia, Inc. (NYSE:PHR) CFO Sells 864 Shares of Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 864 shares of the company’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $21.03, for a total transaction of $18,169.92. Following the transaction, the chief financial officer now directly owns 97,714 shares of the company’s stock, valued at approximately $2,054,925.42. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Balaji Gandhi also recently made the following trade(s):

• On Tuesday, September 10th, Balaji Gandhi sold 3,502 shares of Phreesia stock. The shares were sold at an average price of $23.25, for a total value of $81,421.50.

Phreesia Trading Down 2.2 %

NYSE PHR traded down $0.45 on Thursday, hitting $20.40. 434,344 shares of the stock were exchanged, compared to its average volume of 450,865. The firm has a market capitalization of $1.17 billion, a P/E ratio of -9.45 and a beta of 0.93. Phreesia, Inc. has a 52-week low of $12.05 and a 52-week high of $29.16. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.77 and a current ratio of 1.77. The stock has a fifty day moving average price of $23.40 and a two-hundred day moving average price of $22.45.

Phreesia (NYSE:PHR) last issued its earnings results on Wednesday, September 4th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.06. The firm had revenue of $102.12 million during the quarter, compared to analyst estimates of $101.76 million. Phreesia had a negative net margin of 25.73% and a negative return on equity of 39.34%. Research analysts forecast that Phreesia, Inc. will post -1.23 EPS for the current fiscal year.

Institutional Trading of Phreesia

A number of large investors have recently made changes to their positions in the stock. nVerses Capital LLC raised its holdings in shares of Phreesia by 76.5% in the second quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock valued at $64,000 after acquiring an additional 1,300 shares in the last quarter. EntryPoint Capital LLC bought a new position in Phreesia in the first quarter worth about $169,000. Quadrature Capital Ltd bought a new position in Phreesia in the first quarter worth about $202,000. Lombard Odier Asset Management USA Corp bought a new position in Phreesia in the second quarter worth about $202,000. Finally, ProShare Advisors LLC grew its stake in shares of Phreesia by 8.6% during the first quarter. ProShare Advisors LLC now owns 9,522 shares of the company’s stock worth $228,000 after acquiring an additional 751 shares during the last quarter. 92.10% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on PHR. Royal Bank of Canada reiterated a “sector perform” rating and issued a $23.00 price objective on shares of Phreesia in a report on Friday, September 27th. Robert W. Baird raised their price target on shares of Phreesia from $31.00 to $34.00 and gave the company an “outperform” rating in a report on Friday, September 6th. Needham & Company LLC reiterated a “buy” rating and issued a $29.00 price objective on shares of Phreesia in a research note on Thursday, September 5th. KeyCorp lowered their price objective on shares of Phreesia from $27.00 to $25.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Finally, Truist Financial raised their target price on shares of Phreesia from $29.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, September 6th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $29.42.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.